Navigation Links
Alzheimer's Drug Discovery Foundation Expands its ADDF ACCESS Program to Improve Quality and Efficiency of Drug Research for Neurodegenerative Diseases
Date:11/6/2013

NEW YORK, Nov. 6, 2013 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced yesterday the launch of its newly expanded ADDF ACCESS program to provide scientists in academia and small biotechnology companies with access to a virtual network of drug discovery experts and contract research organizations (CROs) that have experience developing therapies for neurodegenerative diseases. Through the effective selection of CROs and use of their services, researchers may be able to accelerate their research and bring novel therapies to patients faster.  

(Logo: http://photos.prnewswire.com/prnh/20130909/DC75486LOGO)

"The ADDF is excited to expand the availability of this valuable resource for the scientific community," said Howard Fillit, MD, executive director and chief science officer of the ADDF. "Our mission at the ADDF is to accelerate the discovery and development of new Alzheimer's drugs. Drug discovery is a true interdisciplinary effort and ADDF ACCESS seeks to connect scientists with the diverse range of resources and services they need to expedite their research."

ADDF ACCESS now gives academic and small biotechnology research communities access to a network of more than 130 CROs and the services they provide. The expanded and redesigned portal allows users to customize their search for CROs and access a virtual network of drug discovery experts who can provide guidance on CRO selection and research design.

To make this resource available to the broader community and promote collaboration between scientists working on different neurodegenerative diseases, the ADDF is building a consortium of nonprofit partners. BrightFocus Foundation and Beyond Batten Disease Foundation (BBDF) have already provided support for the expansion of ADDF ACCESS.

"When budgets are tight, efficient networking and collaborations are key to research successes," said Guy Eakin, Ph.D., vice president of scientific affairs at BrightFocus Foundation. "We're proud to partner with ADDF to accelerate Alzheimer's drug research through the sharing of critical resources."

Danielle Kerkovich, PhD, principal scientist at BBDF, said, "We are thrilled to be a part of ADDF ACCESS, helping to close the gap between discovery and treatment. With so many Americans, both young and old, facing the threat of serious neurodegenerative diseases, we must bring together the brightest minds, highest quality of resources, and the most experience to save time, money, and lives."

The expansion of ADDF ACCESS was launched in conjunction with the 5th annual Partnering for Cures meeting in New York City. The ADDF ACCESS program was selected as an Innovator Presentation and was presented on Tuesday, November 5, 2013 10:45 – 11:10 AM EST.

About the Alzheimer's Drug Discovery Foundation (ADDF)
The mission of the Alzheimer's Drug Discovery Foundation (ADDF) is to accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. The ADDF has granted nearly $60 million to fund 400 Alzheimer's drug discovery programs and clinical trials in academic centers and biotechnology companies in 18 countries. For more information, please visit www.AlzDiscovery.org.


'/>"/>
SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
2. Berg Receives Frost & Sullivan 2013 Drug Discovery Technology Innovation Award
3. Metabolic Solutions Development Company presents Phase 2a clinical trial results at the 14th International Conference on Alzheimers Drug Discovery
4. KemPharm Continues to Expand its Pain Therapy Pipeline with Discovery of KP606, a Novel Prodrug of Oxycodone
5. Novel Use of Pressure BioSciences Patented PCT Platform Offers New Insights into Protein Structure and Function, New Tool for Biomarker Discovery and Rational Drug Design
6. Alzheimers Drug Discovery Foundation Supports Madera Biosciences to Advance Small Molecule Drugs that Upregulate apoE
7. Discovery Labs Presents Final Assessment in a Series of Pharmacoeconomic Analyses that Explore Impact of Reintubation on Healthcare Costs
8. Quantum Materials Tetrapod Quantum Dots Break Kashas Rule: Enhanced Performance Enables Commercialization of Novel Discovery
9. Novira Therapeutics Expands Management Team with Appointment of Klaus Klumpp, Ph.D., the Former Global Head of Roches Virology Discovery Initiatives, as Vice President Discovery Research
10. Second Genome Announces Agreement with Janssen on Microbiome Drug Discovery in Ulcerative Colitis
11. Cardinal Health Selects Datameer for Healthcare Data Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , February 11, 2016 Breast Cancer ... the Asia-Pacific (APAC) breast cancer market ... $3.4 billion by 2021, at a Compound Annual Growth Rate ... Asia-Pacific Markets to 2021 - states that the ... considerable expansion from $1.9 billion in 2014 to $3.4 billion ...
(Date:2/11/2016)... 11, 2016 --> ... new research report, titled "Sports Medicine Devices Market - Global ... 2019". According to the report, the global sports medicine devices ... 2013 to 2019, growing from a value of US$6.1 bn ... --> --> The global sports medicine devices ...
(Date:2/11/2016)... Jeffrey Zucker , vice president ... present at this year,s Summit for Clinical Operations Executives (SCOPE), ... Miami, FL. Zucker will discuss how sponsors ... supporting SCOPE,s "Improving Site Study Activation and Performance" portion of ... 25 at 11:05 a.m. --> ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... The ... among the top five firms in the “2015/2016 Best in KLAS: Software and ... Staffing. KLAS is a research and insights firm on a global mission to ...
(Date:2/11/2016)... FL (PRWEB) , ... February 11, 2016 , ... ... and advocates will discuss how to improve care by making data on heart ... heart disease. The Summit on Transparency and Public Reporting of Pediatric and Congenital ...
(Date:2/11/2016)... ... , ... In a new paper published in the latest ... J. Rohrich, and colleagues, examine and underscore the importance of upper lateral cartilage ... addressing this vital area. , The upper lateral cartilage in rhinoplasty, refers to ...
(Date:2/11/2016)... ... February 11, 2016 , ... veEDIS Clinical ... technology, with highly adaptable algorithms, has been updated to help Emergency Department physicians ... symptoms consistent with Zikas and a travel history to affected regions, or potential ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... trainer and author Ray Clarke poses a question as a challenge for his ... his book, "Being in the Being" (published by Partridge Singapore), Clarke explores the ...
Breaking Medicine News(10 mins):